-

02:40:37 PM

BPTS Stock News

BPTS - Biophytis

09/27/23 5:45 PM

Nasdaq : BPTS

low float

Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations

Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA)Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first, opening up the prospect of partnershipsCash position and secured financing

RHEA-AI

neutral

09/25/23 1:30 AM

Nasdaq : BPTS

partnershiplow float

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with

RHEA-AI

neutral

09/19/23 1:40 AM

Nasdaq : BPTS

covid-19low float

Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with

RHEA-AI

neutral

09/14/23 1:30 AM

Nasdaq : BPTS

managementlow float

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with

RHEA-AI

neutral

09/11/23 1:20 AM

Nasdaq : BPTS

clinical triallow float

Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 11,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes

RHEA-AI

neutral

09/04/23 5:30 PM

Nasdaq : BPTS

conferenceslow float

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 4, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the

RHEA-AI

neutral

08/16/23 1:15 AM

Nasdaq : BPTS

low float

Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project

PARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / August 16, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated

RHEA-AI

neutral

08/08/23 1:20 AM

Nasdaq : BPTS

clinical triallow float

Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated

RHEA-AI

neutral

07/20/23 1:20 AM

Nasdaq : BPTS

acquisitioncovid-19low float

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 20, 2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated

RHEA-AI

neutral

07/19/23 2:20 AM

Nasdaq : BPTS

offeringlow float

Biophytis Announces $3.8 Million Registered Direct Offering

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / July 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next